US price erosion and competitive pressure
US generic market faces low single-digit price erosion; margins remain under pressure from competition.
GLENMARK / Q2-FY25 / risks
Keep the risk register visible.
Glenmark Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Monroe plant delay
Monroe plant has been non-operational; any further delay in FDA clearance could prolong the $25-26M annual cash burn.
Supply constraints for Lirafit
Lirafit (GLP-1 biosimilar) faced supply issues; resolution expected from December but could impact scaling.
ROW growth slowdown
ROW revenue declined 4.1% YoY due to high base and geopolitical challenges; full-year growth guided at high single digit.